Helicobacter Pylori

Roughly half the world carries a stomach bug that quietly drives ulcers, chronic gastritis, and most stomach cancers. It often causes no symptoms for years, which is exactly why finding it matters. A stool PCR test can tell you whether you have it without an endoscopy.

What makes this test stand out is that the better assays do two things at once. They detect the bacterium and they read the genetic mutations that determine whether the standard first-line antibiotic will work, so treatment can be matched to your specific infection from the start.

What This Test Actually Detects

Stool PCR for H. pylori (Helicobacter pylori) looks for fragments of the bacterium's DNA passed in your stool. The lab amplifies specific genetic targets such as glmM, ureA, or 16S rRNA (genetic markers unique to the bacterium) to confirm the organism is present. Modern assays also scan the 23S rRNA gene for mutations that cause clarithromycin resistance, and some look at gyrA for levofloxacin resistance.

A positive result generally means the bacterium is actively colonizing your stomach, since PCR detects the organism's DNA. A negative result means no detectable DNA was shed during that sample, which usually means you are not infected or have been successfully treated. The test reads current biology, not a history of past exposure, which is how it differs from a blood antibody test.

Why Finding It Matters

H. pylori is the single biggest infectious cause of stomach cancer, and the World Health Organization's cancer agency classifies it as a definite human carcinogen. In one diagnostic cohort of infected adults referred for endoscopy, 56.5% had gastritis, about 11.6% had a stomach or duodenal ulcer, and 31.2% had precancerous or cancerous changes including atrophy, metaplasia, dysplasia, and adenocarcinoma. These percentages reflect a referred symptomatic population, not all carriers, since most carriers never know they have it until damage has started.

Stomach Cancer Risk

The strongest argument for finding and treating H. pylori is long-term cancer prevention. In a randomized trial of 1,630 infected adults followed for 26.5 years, eradication therapy reduced stomach cancer from 4.31% in the placebo group to 2.57% in the treatment group, a roughly 43% relative reduction in risk. People who were successfully cleared of the bacterium had less than half the cancer risk of those who stayed infected.

About 10% of people with chronic H. pylori develop ulcers, and a smaller fraction (roughly 1 to 3% of infected individuals) progress along a cascade from gastritis to atrophy, metaplasia, dysplasia, and eventually adenocarcinoma. Catching infection earlier short-circuits that cascade before precancerous changes set in.

Ulcers and Chronic Gastritis

H. pylori is the dominant cause of stomach and duodenal ulcers in people not taking heavy doses of NSAID painkillers. The infection drives chronic inflammation of the stomach lining, which can present as nagging upper abdominal pain, bloating, nausea, or no symptoms at all. Eradication heals most ulcers and dramatically reduces the chance of recurrence.

MALT Lymphoma

A rarer but striking association is gastric MALT lymphoma, a low-grade cancer of immune tissue in the stomach lining. Many early-stage MALT lymphomas actually regress after H. pylori is eradicated, which is one of the cleanest examples in medicine of treating an infection to treat a cancer.

Iron and B12 Deficiency

Chronic infection can also quietly contribute to iron deficiency anemia, vitamin B12 deficiency, and idiopathic thrombocytopenic purpura, a low-platelet condition. If you have unexplained low iron, low B12, or stubborn anemia and your doctor cannot find a clear cause, testing for H. pylori is part of the workup that current guidelines support.

Reading a Resistance Result

Many modern stool PCR panels also report whether your strain carries mutations linked to clarithromycin resistance, and sometimes levofloxacin resistance. This matters enormously for treatment. In one stool PCR study, standard clarithromycin triple therapy succeeded in only 41% of people whose strain carried resistance mutations versus 70% in those without. In another cohort, resistant infections were eradicated far less often than susceptible infections (roughly 38.5% vs. 97.2% in that report, though specific figures vary by study).

In practice, a resistance signal from PCR helps your clinician skip the antibiotic that will likely fail and pick a regimen that has a real chance of clearing the infection on the first try. Real-world programs that picked therapy based on stool PCR resistance results reached around 91% eradication, far above the failure-prone empiric approach.

How It Compares to Other H. pylori Tests

Several tests can detect H. pylori, and each has tradeoffs. The table below summarizes the main options.

Source: Pichon et al. 2020 and Zhang et al. 2023 meta-analysis for real-time PCR sensitivity; Khadangi et al. 2017 meta-analysis for the older pooled estimate; Al Qady et al. 2024 and Gong et al. 2021 meta-analyses for resistance detection.

What this means for you: if you want a noninvasive option that also tells you whether the cheapest first-line antibiotic will work, stool PCR is the most informative single test in this category.

When Results Can Be Misleading

A few specific situations can distort a stool PCR result. Most are about timing and sample handling, not the underlying biology.

• Recent antibiotics: any antibiotic course in the prior 4 weeks can suppress the organism enough to give a false-negative result, even if you are still infected.
• Recent bismuth or PPI use: bismuth subsalicylate and acid-suppressing drugs like omeprazole, esomeprazole, and pantoprazole reduce bacterial numbers in the stomach. Stool PCR is more robust than the urea breath test, but guideline recommendations on how long to pause these drugs differ. The 2024 ACG guideline recommends stopping bismuth and antibiotics for 4 weeks and a PPI (proton pump inhibitor, a strong acid-suppressing drug) for at least 2 weeks, while an earlier US recommendation cited in a 2019 NEJM review used 30 days for both PPIs and antibiotics. Erring on the longer side is the safer setup.
• Watery or delayed samples: very loose stool dilutes DNA and degrades it during transit. Samples held more than 24 to 48 hours without a stabilizing collection kit can lose accuracy.
• Mixed strains: if both resistant and sensitive populations of H. pylori are in the stomach at once, the resistant signal can be drowned out, especially in people who have never been treated before.

Tracking Your Result Over Time

Unlike a cholesterol or hormone level, H. pylori PCR is mostly a yes-or-no test. The point of repeat testing is to confirm eradication after treatment and to detect reinfection. The standard cadence is straightforward: test once when you have a reason to suspect infection, treat if positive, then retest at least 4 weeks after finishing antibiotics and any PPI, using stool PCR or a urea breath test to confirm the bug is gone.

Repeating earlier than that risks a false-negative because the bacterial population has not yet bounced back. After confirmed eradication, reinfection in adults in most developed-country settings is low, though it is higher in high-prevalence regions. A fresh test is reasonable if symptoms return or if family members test positive. People with a strong family history of stomach cancer should have a lower threshold to retest if symptoms recur.

What To Do With a Positive Result

A positive stool PCR is a clear call to action. The pathway depends on what else the report shows.

• Positive with no resistance flagged or no resistance testing done: the 2024 ACG guideline strongly recommends bismuth quadruple therapy (a proton pump inhibitor plus bismuth plus two antibiotics, usually tetracycline and metronidazole) for 10 to 14 days, with 14 days preferred. This achieves around 90% eradication in modern trials. Rifabutin triple therapy and vonoprazan-based dual therapy are listed as alternative first-line options.
• Positive with clarithromycin resistance flagged: clarithromycin-based triple therapy is no longer the right choice. Bismuth quadruple therapy, a high-dose dual regimen, or a regimen using vonoprazan (a newer potassium-competitive acid blocker, FDA-approved for H. pylori) with amoxicillin is preferred. Tegoprazan, another potassium-competitive acid blocker, is used in some countries but is not FDA-approved in the US and has less established evidence.
• Positive with persistent or severe upper GI symptoms, alarm signs (weight loss, vomiting blood, black stools, trouble swallowing), or a strong family history of stomach cancer: referral to a gastroenterologist for upper endoscopy is appropriate to look directly at the stomach lining for ulcers, atrophy, metaplasia, or early cancer.
• Positive in a household: because infection clusters within families and reinfection is more common when other members carry it, current evidence and the 2025 AGA update support testing close household contacts and treating those who are positive.

About 4 weeks after completing therapy, confirm eradication with a repeat stool PCR or a urea breath test. Do not assume a course of antibiotics worked, especially if the original test flagged resistance or you have been treated for H. pylori in the past.